患者在心房开始服用口服抗凝剂的观点:一项探索性定性描述性研究
Eyob Alemayehu Gebreyohannes1, Sandra M Salter1, Leanne Chalmers2
1Division of Pharmacy, School of Allied Health, The University of Western Australia, Crawley 6009, WA, Australia.
Pharmacy (Basel, Switzerland)
|October 27, 2023
概括
当医生清楚地解释风险和益处,并将治疗与患者的目标相协调时,患者同意开始治疗心房的口服抗凝剂 (OAC) 得到改善. 了解这些因素可以提高抗凝治疗效果.
科学领域:
- 心脏病学 心脏病学
- 一般的做法一般的做法
- 患者的坚持 患者的坚持
背景情况:
- 口服抗凝剂 (OAC) 对于降低心房患者中风风险至关重要.
- 患者拒绝启动OACs对有效的抗凝固药物构成重大挑战.
- 了解患者的观点是改善OAC吸收的关键.
研究的目的:
- 探索影响患者同意开始OACs的障碍和促进者.
- 收集来自澳大利亚通用诊所的AF患者的见解.
- 为提高OAC启动和坚持的战略提供信息.
主要方法:
- 定性描述性研究设计.
- 在2022年3月至7月期间进行的半结构化个人访谈.
- 涉及来自澳大利亚一般诊所的十名AF患者.
主要成果:
- 患者在决策中的被动作用促进了OAC的协议.
- 适当的医生解释,与患者健康目标 (中风预防) 保持一致,并了解OAC的利弊是关键促进因素.
- 缺乏充分的解释和华法林的不便被认为是障碍.
结论:
- 解决患者同意因素对于改善抗凝治疗的质量至关重要.
- 进一步的研究应该探索患者拒绝OAC的观点以及关于OAC延续的决定.
- 整合以患者为中心的沟通策略可以改善AF患者的OAC启动.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Anticoagulant Drugs: Low-Molecular-Weight Heparins
723
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
723
Venous Thrombosis IV: Nursing Management
14
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
14
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
537
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
537
Acute Coronary Syndrome IV: Interprofessional Care
11
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
11


